Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
2.530
0.00 (0.00%)
At close: Feb 27, 2026, 4:00 PM EST
2.550
+0.020 (0.79%)
After-hours: Feb 27, 2026, 7:15 PM EST
Adial Pharmaceuticals Employees
Adial Pharmaceuticals had 5 employees as of December 31, 2024. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,610,360
Market Cap
2.81M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| Dermata Therapeutics | 8 |
| Enveric Biosciences | 6 |
| Artelo Biosciences | 5 |
| Oragenics | 5 |
| GRI Bio | 4 |
| XORTX Therapeutics | 3 |
ADIL News
- 4 days ago - Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement - GlobeNewsWire
- 5 days ago - Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One - GlobeNewsWire
- 24 days ago - Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 - GlobeNewsWire
- 25 days ago - Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
- 4 months ago - Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show - GlobeNewsWire
- 5 months ago - Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution - GlobeNewsWire
- 5 months ago - Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04 - GlobeNewsWire
- 6 months ago - Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule - GlobeNewsWire